Navigation Links
ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
Date:2/26/2008

TORONTO, Feb. 26 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that five abstracts have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California. The Company will deliver presentations that will disclose new findings about its CD44, TROP-2, CD59, and CD9 antibody programs.

"The inclusion of five ARIUS abstracts in this conference is a significant achievement, demonstrating the scientific community's interest in our programs and the high quality of our research," said Dr. David Young, President and CEO. "Among these abstracts are findings from our cancer stem cell programs targeting CD44 and CD9. This is an exciting new area of cancer research and as we prepare our CD44 antibody to enter human clinical trials this year, we believe we will have one of the only novel cancer stem cell drugs entering clinical trials in the near-term."

The following ARIUS' abstracts will be presented:

Abstract Number 3975:

"Preclinical development of huARH460-16-2, a humanized antibody to the CD44 cancer stem cell target." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3976:

"Anti-CD44 antibody, ARH460-16-2, binds to human AML CD34+CD38- cancer stem cells and demonstrates anti-tumor activity in an AML xenograft model." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3990:

"AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3993:

"Anti-CD9 antibody, AR40A746.2.3, inhibits tumor
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
5. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
6. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
7. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
8. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
9. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. ARIUS to present at Chinese Global Financial Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
Breaking Biology Technology:Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... NeuroCog Trials, Inc. today announced the appointment of Michael ... Officer.  In this newly created position, Dr. Hufford will ... NeuroCog Trials, business, research and development, and operations. ... therapies across a wide variety of therapeutic areas has ...
... November 4, 2011 Major milestone achieved ... treatment of patients with refractory ascites due to liver ... Vienna and Vienna General Hospital (AKH Wien) reported that ... System were performed at Vienna General Hospital in October, ...
... Nov. 3, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... total revenues of $13.6 million for the third quarter of 2011, ... the third quarter of 2010.  Net loss for the third quarter ... to net loss of $22.7 million, or $0.30 per share for ...
Cached Biology Technology:NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 2Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 3Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 4Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 5Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 6Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 7Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011 8
(Date:10/30/2014)... University researchers have developed a suite of technologies that ... humans, which has applications in everything from search and ... "We,ve developed a platform for computer-mediated communication between humans ... for interpreting dogs, behavioral signals and sending them clear ... an assistant professor of computer science at NC State ...
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... have found that a strain of tuberculosis (TB) responsible ... first introduced to these communities by French Canadian fur ... found a traceable link between the fur trade routes ... professor with Queen,s Division of Infectious Diseases, is the ...
... Melding nanotechnology and medical research, Sandia National Laboratories, the ... and Treatment Center have produced an effective strategy that ... of killer drugs. , In the cover article of ... online April 17 , the researchers describe silica nanoparticles ...
... Monday, April 18, 2011, Cleveland: Researchers have identified ... as the cause of a fatal developmental disease in ... April 8, 2011, issue of Science . ... the cellular protein-making process, causing microcephalic osteodysplastic primoridal dwarfism ...
Cached Biology News:Tuberculosis strain in indigenous communities linked to Canadian fur trade 2Sandia and UNM lead effort to destroy cancers 2Sandia and UNM lead effort to destroy cancers 3Genetic mutation linked to lethal disease 2
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Biology Products: